Various ETFs have experienced an uptick in ETF outflows since the year began. Undoubtedly, the recent March correction driven by mounting tariff fears has pushed investors to take profits and rotate towards more defensive names.
The company, which went public in 2021, has never turned a profit. Transcript: Loren Torres: 23andMe, which gave customers “personalized genetic insights” through its at-home DNA testing kits, has filed for bankruptcy.
Several stocks have been gaining big attention as of late, a list that includes Alibaba BABA, Palantir PLTR, and Vertiv VRT. Let's take a closer look at each to see how they presently stack up.
Uncertainty is the market's current buzz word. Concerns about policy, recession risk, inflation, consumer confidence, economic growth, and geopolitics have stock prices on a rollercoaster ride this year.
The VictoryShares Free Cash Flow ETF (VFLO) has generated strong returns for investors while potentially avoiding value traps. VFLO provides exposure to large-cap companies with high free cash flow (FCF).
REITs are offering a historic opportunity. But not all REITs are worth buying. I highlight 3 popular to sell.
Momentum stocks popular with the retail crowd continued to slide on Tuesday, adding to their woes from the past week.
Palantir Technologies (PLTR -4.63%) and Super Micro Computer (SMCI -5.40%) are two of the most popular artificial intelligence (AI) stocks on the market. But certain Wall Street analysts have set the companies with target prices that imply substantial downside in the next year.
Advances in the field of artificial intelligence (AI) over the past couple of years have come fast and furious. Arguably, one of the biggest beneficiaries of this trend is Nvidia (NVDA 0.40%).
Popular, Inc.'s Series A Preferred Shares offer a yield near 6.5% with monthly dividends that have been paid without interruption for more than 20 years. Puerto Rican banks, including Popular, Inc., benefit from an oligopolistic market. Popular, Inc. has improved several financial metrics since I last covered its Series A Preferred Shares in 2020.
Ozempic and other semaglutide drugs help people reduce their drinking, a new study has found.
I focus on finding great stocks rather than avoiding bad ones - good investments are rare, while weak stocks are easy to spot. This approach adds more value. Bearish articles often lead to defensive reactions rather than insightful discussions. I prefer constructive engagement, making my analysis more valuable to readers. That said, I highlight a few well-known dividend stocks I would avoid. My goal isn't to convince anyone to sell, but to provide food for thought and perspective.